De-escalation of Monotherapy with P2Y12 Inhibitor. An Alternative Approach

As dual anti-platelet therapy (DAPT) duration in acute coronary syndrome (ACS) remains debated, insight on de-escalation to P2Y12 inhibitor monotherapy is critical. In this expert talk, the speaker analyzes European guidelines and consensus recommendations on shortening DAPT after percutaneous coronary intervention. Gain an in-depth look at the evidence for 1-3 month DAPT followed by P2Y12i monoth...